Cara Therapeutics (CARA) PT Raised to $27 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
Cara Therapeutics (CARA) PT Raised to $34 at Piper Jaffray
July 24, 2015 11:30 AM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Cara Therapeutics (NASDAQ: CARA) to $34.00 (from $30.00) after the company announced positive results from its Phase II study of IV CR845 in Uremic Pruritus (UP), which achieved the primary endpoint... More
Cara Therapeutics (CARA) Fair Value Target Lifted to $27 at Janney Capital
July 23, 2015 10:45 AM EDTJanney Capital analyst Chiara Russo raised her fair value target on Cara Therapeutics (NASDAQ: CARA) to $27.00 (from $25.00) announced positive top-line data this morning for IV CR845 in its Phase 2 Proof-of-Concept (POC) trial for dialysis itch, which hit statistical significance not just on the primary... More
Cara Therapeutics (CARA) Announces Statistically Significant Results From Phase 2 Trial in Uremic Pruritus
July 23, 2015 8:45 AM EDTCara Therapeutics, Inc. (Nasdaq: CARA) today announced statistically significant topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP). Uremic pruritus is a chronic systemic itch condition in patients with renal failure, often receiving hemodialysis. There are currently no approved products in the United States for the condition.
"These results demonstrate the potential of our lead candidate CR845 to address an additional indication of significant unmet need beyond our lead I.V. CR845 program in acute pain," said... More
